The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2015

Filed:

Apr. 08, 2014
Applicant:

The University of British Columbia, Vancouver, CA;

Inventors:

Martin E. Gleave, Vancouver, CA;

Scott D. Cormack, Vancouver, CA;

Assignee:

The University of British Columbia, Vancouver, British Columbia, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 31/711 (2006.01); C12N 15/11 (2006.01); A61K 31/7052 (2006.01); A61K 31/337 (2006.01); A61K 31/7068 (2006.01); A61K 31/7105 (2006.01); A61K 33/24 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/337 (2013.01); A61K 31/7052 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 31/711 (2013.01); A61K 31/7105 (2013.01); A61K 33/24 (2013.01); A61N 5/10 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2320/31 (2013.01);
Abstract

A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.


Find Patent Forward Citations

Loading…